Gene Therapy Shows Promise in Treating Rare Eye Disease in Mice
April 14, 2021
Rare Daily Staff
A gene therapy protects eye cells in mice with a rare disorder that causes vision loss, especially when used in combination with other gene therapies, researchers report in a new study.
The study, published in eLife, suggests that this therapy, whether used alone or in combination with other gene therapies that boost eye health, may offer a new approach to preserving vision in people with retinitis pigmentosa or other conditions that cause vision loss.
Retinitis pigmentosa is a slowly progressive disease, which begins with the loss of night vision due to genetic lesions that affect rod photoreceptors—cells in the eyes that sense light when it is low. These photoreceptors die because of their intrinsic genetic defects. This then impacts cone photoreceptors, the eye cells that detect light during the day, which leads to the eventual loss of daylight vision.
While scientists have developed a few targeted gene therapies to help individuals with certain mutations that affect the photoreceptors, no treatments are currently available that would be effective for a broad set of families with the disease.
“A gene therapy that would preserve photoreceptors in people with retinitis pigmentosa regardless of their specific genetic mutation would help many more patients,” said Yunlu Xue, postdoctoral fellow in Constance Cepko’s lab at Harvard Medical School and lead author of the study.
To find a widely effective gene therapy for the disease, Xue and colleagues screened 20 potential therapies in mouse models with the same genetic deficits as humans with retinitis pigmentosa. The team chose the therapies based on the effects they have on sugar metabolism. One theory about why cones die concerns the loss of nutrient supply, especially glucose.
Their experiments showed that using a virus carrier to deliver a gene called Txnip was the most effective approach in treating the condition across three different mouse models. A version of Txnip called C247S worked especially well, as it helped the cone photoreceptors switch to using alternative energy sources and improved mitochondria health in the cells.
The team then showed that giving the mice gene therapies that reduced oxidative stress and inflammation, along with Txnip gene therapy, provided additional protection for the cells. Further studies are now needed to confirm whether this approach would help preserve vision in people with retinitis pigmentosa.
The researchers said the next step will be to test Txnip for safety in animals beyond mice before moving on to a clinical trial in humans. If proven safe the researchers hope it could become a treatment for retinitis pigmentosa and other forms of progressive vision loss, such as age-related macular degeneration.
Photo: Yunlu Xue, postdoctoral fellow in Constance Cepko’s lab at Harvard Medical School and lead author of the study
Sign up for updates straight to your inbox.